Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SJP-005
- Development stage
- Preclinical
- Lead developer
- Sen-Jam Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SJP-005 is an investigational non-opioid combination drug candidate being developed by Sen-Jam Pharmaceutical for the treatment of stimulant withdrawal and opioid use disorder. The product is a fixed-dose combination of the non-steroidal anti-inflammatory drug (NSAID) **ketoprofen** and the first-generation antihistamine **diphenhydramine**. SJP-005 is designed to target the neuroinflammatory pathways associated with drug withdrawal, craving, and relapse. Preclinical research conducted in collaboration with the National Institute on Drug Abuse (NIDA) demonstrated that SJP-005 significantly reduced methamphetamine-induced hyperactivity and withdrawal symptoms in rodent models. Sen-Jam has partnered with KVK Tech to manage the formulation and Chemistry, Manufacturing, and Controls (CMC) development of the asset in preparation for an Investigational New Drug (IND) application.
- Other names
- ketoprofen + diphenhydramine
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on SJP-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SJP-005.